Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.
Virus-like particles have proved to be excellent molecular scaffolds, yet the individual characteristics and immune responses generated against each VLP requires the development of a wide range of capsids for use as vaccines, molecular delivery vessels, and nanoscale templates. Here we describe the development of Rabbit haemorrhagic disease virus (RHDV)-like particles as a rapidly versatile molecular workbench, overcoming limitations imposed by established genetic antigen incorporation procedures with chimeric VLP. Production of the RHDV capsid protein in a baculovirus system led to the self-assembly of VLP which were recovered at over 99% purity and manipulated both genetically and chemically. Fusion of small peptide sequences to RHDV VLP was well tolerated, forming chimeric capsids that enhanced the presentation of foreign peptide to hybridoma T helper cells 700-fold. Rapid and simple conjugation techniques employing the hetero-bifunctional chemical linker sulfo-SMCC enabled both small peptides and whole proteins to be conjugated to the surface of RHDV VLP, overcoming limitations imposed on VLP formation and yield experienced with chimeric VLP. Administration of VLP/ovalbumin conjugate provoked high titre ovalbumin-specific antibody in mice, demonstrating the immune stimulatory properties of the capsid were conferred to conjugated foreign antigen. VLP facilitated delivery of conjugated antigen to dendritic cells, eliciting proliferative responses in naïve TCR transgenic T helper cells that were at least 10-fold greater than ovalbumin antigen delivered alone.
Peacey
Matthew
M
Department of Microbiology & Immunology, School of Medical Sciences, University of Otago, P.O. Box 56, Dunedin, 9054, New Zealand.
Wilson
Sarah
S
Baird
Margaret A
MA
Ward
Vernon K
VK
D000217:Acyltransferases / Q000737:chemistry; D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D017951:Antigen Presentation / Q000276:immunology; D000941:Antigens / Q000737:chemistry / Q000235:genetics / Q000276:immunology*; D000942:Antigens, Bacterial / Q000737:chemistry; D002213:Capsid / Q000737:chemistry / Q000276:immunology / Q000648:ultrastructure; D003713:Dendritic Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D049452:Green Fluorescent Proteins / Q000737:chemistry; D006388:Hemagglutinins / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D017929:Hemorrhagic Disease Virus, Rabbit / Q000737:chemistry* / Q000235:genetics; D008213:Lymphocyte Activation / Q000276:immunology; D008301:Maleimides / Q000737:chemistry; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D016253:Microscopy, Immunoelectron; D010446:Peptide Fragments / Q000737:chemistry / Q000235:genetics / Q000276:immunology; D011817:Rabbits; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D014611:Vaccination; D014614:Vaccines, Synthetic / Q000096:biosynthesis / Q000737:chemistry / Q000276:immunology; D015678:Viral Structural Proteins / Q000737:chemistry* / Q000235:genetics / Q000276:immunology
D000941:Antigens; D000942:Antigens, Bacterial; D018984:Epitopes, T-Lymphocyte; D006388:Hemagglutinins; D008301:Maleimides; D010446:Peptide Fragments; D011994:Recombinant Proteins; D014614:Vaccines, Synthetic; D015678:Viral Structural Proteins; C485184:enhanced green fluorescent protein; C071675:sulfosuccinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate; C081149:viral protein 60, rabbit hemorrhagic disease virus; D049452:Green Fluorescent Proteins; D000217:Acyltransferases; C112580:antigen 85A, Mycobacterium tuberculosis